Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
- PMID:3513012
- DOI: 10.1056/NEJM198603203141201
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
Abstract
We treated 93 patients who had acute nonlymphoblastic leukemia in the first remission or chronic myelocytic leukemia in the chronic phase (median age, 30 years) with high-dose cyclophosphamide and fractionated total-body irradiation, followed by infusion of marrow from an HLA-identical sibling. To evaluate postgrafting prophylaxis for graft versus host disease, we studied these patients in a sequential, prospective, randomized trial that compared the effect of a combination of methotrexate and cyclosporine (n = 43) with that of cyclosporine alone (n = 50). All patients had evidence of sustained engraftment. A significant reduction in the cumulative incidence of grades II to IV acute graft versus host disease was observed in the patients who received both methotrexate and cyclosporine (33 percent), as compared with those who were given cyclosporine alone (54 percent) (P = 0.014). Seven patients who received cyclosporine alone acquired grade IV acute graft versus host disease, as compared with none who received both methotrexate and cyclosporine. Thirty-five of the 43 patients given both methotrexate and cyclosporine and 31 of the 50 patients given cyclosporine are alive as of this writing, at 4 months to 2 years (median, 15 months); the actuarial survival rates in the two groups at 1.5 years were 80 percent and 55 percent, respectively (P = 0.042). We conclude that the combination of methotrexate and cyclosporine is superior to cyclosporine alone in the prevention of acute graft versus host disease after marrow transplantation for leukemia, and that this therapy may have a beneficial effect on long-term survival.
Similar articles
- Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J, et al.Storb R, et al.Blood. 1986 Jul;68(1):119-25.Blood. 1986.PMID:3521761Clinical Trial.
- Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial.Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R, et al.Storb R, et al.Blood. 1989 May 1;73(6):1729-34.Blood. 1989.PMID:2653461Clinical Trial.
- Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.Storb R, Deeg HJ, Whitehead J, Farewell V, Appelbaum FR, Beatty P, Bensinger W, Buckner CD, Clift RA, Doney K, et al.Storb R, et al.Transplant Proc. 1987 Feb;19(1 Pt 3):2608-13.Transplant Proc. 1987.PMID:3547942Clinical Trial.No abstract available.
- Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.Truog AW, Wozniak SP.Truog AW, et al.Oncol Nurs Forum. 1990 Jan-Feb;17(1):39-44.Oncol Nurs Forum. 1990.PMID:2405360Review.
- Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.Schwinghammer TL, Bloom EJ.Schwinghammer TL, et al.Clin Pharm. 1993 Oct;12(10):736-61.Clin Pharm. 1993.PMID:8258255Review.
Cited by
- Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide-based regimen for prevention of graft-versus-host disease in haploidentical peripheral blood stem cell transplantation for pediatric patients with hematologic malignancies.Du Y, Zhang Y, Xu X, Cai Y, Wei Y, Huang C, Yang J, Qiu H, Niu J, Zhou K, Xia X, Shen C, Tong Y, Dong B, Wan L, Song X.Du Y, et al.Ann Hematol. 2024 Sep;103(9):3765-3774. doi: 10.1007/s00277-024-05883-w. Epub 2024 Jul 10.Ann Hematol. 2024.PMID:38981923
- Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies.Amanam I, Otoukesh S, Al Malki MM, Salhotra A.Amanam I, et al.Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):164-170. doi: 10.1182/hematology.2023000427.Hematology Am Soc Hematol Educ Program. 2023.PMID:38066845Free PMC article.
- Mesenchymal stem cells preconditioned with a TLR5 agonist enhanced immunoregulatory effect through M2 macrophage polarization in a murine graft-versus-host disease model.Gil S, Im KI, Kim N, Lee J, Na H, Min GJ, Cho SG.Gil S, et al.Int J Med Sci. 2024 Jun 17;21(9):1649-1660. doi: 10.7150/ijms.93121. eCollection 2024.Int J Med Sci. 2024.PMID:39006841Free PMC article.
- Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.Hymes SR, Alousi AM, Cowen EW.Hymes SR, et al.J Am Acad Dermatol. 2012 Apr;66(4):535.e1-16; quiz 551-2. doi: 10.1016/j.jaad.2011.11.961.J Am Acad Dermatol. 2012.PMID:22421124Free PMC article.
- Analysis of different protein kinase C-dependent events in T cells from allogeneic bone marrow transplantation recipients.Balboa MA, Izquierdo M, Sánchez-Madrid F, Fernández-Rañada JM, López-Botet M.Balboa MA, et al.Clin Exp Immunol. 1992 Mar;87(3):478-84. doi: 10.1111/j.1365-2249.1992.tb03023.x.Clin Exp Immunol. 1992.PMID:1544233Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials